Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.

[1]  A. Antinori,et al.  Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial , 2014, The Lancet.

[2]  M. Zazzi,et al.  Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments. , 2014, AIDS research and human retroviruses.

[3]  M. Nelson,et al.  Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients , 2014, Journal of acquired immune deficiency syndromes.

[4]  V. Calvez,et al.  National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011. , 2013, The Journal of antimicrobial chemotherapy.

[5]  D. Kuritzkes,et al.  Virologic Response, Early HIV-1 Decay, and Maraviroc Pharmacokinetics With the Nucleos(t)ide-Free Regimen of MaravIroc Plus Darunavir/Ritonavir in a Pilot Study , 2013, Journal of acquired immune deficiency syndromes.

[6]  Atsushi Jinno-Oue,et al.  CCR6 Functions as a New Coreceptor for Limited Primary Human and Simian Immunodeficiency Viruses , 2013, PloS one.

[7]  A. Lazzarin,et al.  Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients. , 2013, Journal of Antimicrobial Chemotherapy.

[8]  D. Podzamczer,et al.  Maraviroc Once-Daily Nucleoside Analog-Sparing Regimen in Treatment-Naive Patients: Randomized, Open-Label Pilot Study , 2013, Journal of acquired immune deficiency syndromes.

[9]  A. Lazzarin,et al.  Immune recovery and T cell subset analysis during effective treatment with maraviroc. , 2012, The Journal of antimicrobial chemotherapy.

[10]  J. Gathe,et al.  Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. , 2012, AIDS research and human retroviruses.

[11]  C. Rouzioux,et al.  Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study. , 2012, The Journal of infectious diseases.

[12]  J. Ainsworth,et al.  Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. , 2012, The Journal of antimicrobial chemotherapy.

[13]  T. Brown,et al.  Bone Turnover, Osteoprotegerin/Rankl and Inflammation with Antiretroviral Initiation: Tenofovir versus Non-Tenofovir Regimens , 2011, Antiviral therapy.

[14]  M. Moroni,et al.  Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. , 2011, The new microbiologica.

[15]  A. Lazzarin,et al.  Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine. , 2011, Journal of acquired immune deficiency syndromes.

[16]  A. Lazzarin,et al.  Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT Trial , 2011, HIV clinical trials.

[17]  G. Fätkenheuer,et al.  Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2 , 2010, Journal of acquired immune deficiency syndromes.

[18]  Wuyuan Lu,et al.  CCR6 ligands inhibit HIV by inducing APOBEC3G. , 2010, Blood.

[19]  J. Routy,et al.  Peripheral Blood CCR4+CCR6+ and CXCR3+CCR6+ CD4+ T Cells Are Highly Permissive to HIV-1 Infection , 2009, The Journal of Immunology.

[20]  T. Rutigliano,et al.  A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load , 2008, Nature Protocols.

[21]  Adeeba Kamarulzaman,et al.  AIDS Res Hum Retroviruses , 2006 .

[22]  R. Haubrich,et al.  Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. , 2006, The Journal of infectious diseases.

[23]  B. Gazzard,et al.  Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. , 2005, The Journal of infectious diseases.

[24]  M. Lederman,et al.  CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. , 2002, Clinical immunology.

[25]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[26]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.